Compare Royal Caribbean Cruises Ltd (RCL) vs Revolution Medicines Inc. Common Stock (RVMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs Revolution Medicines Inc. Common Stock — how do they compare? Royal Caribbean Cruises Ltd trades at $282 (market cap $75.26B), while Revolution Medicines Inc. Common Stock trades at $189.32 (market cap $40.32B). The key difference: Royal Caribbean Cruises Ltd is the larger of the two by market cap, and Royal Caribbean Cruises Ltd pays a 2.13% dividend while Revolution Medicines Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royal Caribbean Cruises Ltd for 85 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| RCL | RVMD | |
|---|---|---|
Market Cap | $75.26B | $40.32B |
Volume | 1,958,628 | 4,855,734 |
Sector | Consumer Cyclical | Health |
52-Week High | $348.03 | $221.15 |
52-Week Low | $230.30 | $47.50 |
Typical Hold Time | 85 Days | 0 Days |
Enterprise Value | $97.91B | $37.02B |
Dividend Yield | 2.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $282.26, showing minimal daily movement (-0.04%) amid strong fundamental performance. The stock maintains a bullish technical outlook with support at $279 and resistance at $284. Recent earnings beats in Q1 and Q2 2026, coupled with robust revenue growth from $8.8B in 2022 to $17.9B in 2025, highlight operational strength. The company's expansion into resort markets through the $3B Sandals acquisition adds growth diversification while analyst consensus remains positive with a $346.67 price target.
RCL presents a compelling growth story with expanding profit margins and strategic diversification, though elevated debt levels and fuel cost sensitivity pose moderate risks. The stock's current valuation at 17.38x P/E appears reasonable given 45.33% ROE and consistent earnings outperformance. Near-term catalysts include Q3 2026 earnings and continued execution on the Sandals integration, while macroeconomic pressures on travel demand represent the primary headwind.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About Revolution Medicines Inc. Common Stock
Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →
